ORMPORAMED PHARMACEUTICALS INC.vs its industry peers
A metric-by-metric comparison of ORAMED PHARMACEUTICALS INC. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORMPThis | $192M#8 | 1.1x#1 | 1.0x#6 | 96.1x#6 | — | 573.1%#2 | -754.4%#4 | 0.0%#3 | -4.4%#2 | — | 97.9%#3 | — |
| KROS | $213M#2 | — | 0.8x#3 | 0.9x#2 | 6775.0%#1 | 146.4%#3 | 27.7%#1 | 33.2%#1 | — | — | -31.9%#9 | — |
| BRVE | $2.5B#1 | — | — | — | — | — | — | — | — | — | — | — |
| NKTX | $206M#3 | — | 0.8x#4 | — | — | 4.3%#7 | — | -42.0%#6 | — | — | 47.9%#5 | — |
| KRRO | $204M#4 | — | 2.0x#10 | 31.9x#5 | 181.5%#2 | -40.3%#10 | -1906.4%#7 | -113.6%#11 | -155.2%#4 | — | -55.7%#11 | — |
| TNXP | $202M#5 | — | 0.9x#5 | 15.4x#4 | 29.8%#3 | 4.6%#6 | -959.1%#5 | -55.8%#9 | -234.8%#5 | — | -56.6%#12 | — |
| ANTX | $202M#6 | — | 2.7x#11 | — | — | 31.5%#4 | — | -46.3%#7 | — | — | 316.0%#2 | — |
| PEPG | $200M#7 | — | 1.7x#8 | — | — | 0.4%#8 | — | -75.0%#10 | — | — | 47.4%#6 | — |
| ORGO | $180M#9 | — | 1.2x#7 | 0.3x#1 | 17.0%#4 | 4011.1%#1 | 7.9%#2 | 25.0%#2 | 23.2%#1 | — | -71.3%#13 | — |
| NERV | $167M#10 | — | — | — | — | -20492.7%#13 | — | — | — | — | 55.1%#4 | — |
| RNA | $163M#11 | — | 0.8x#2 | — | — | — | — | 0.0%#4 | — | — | -77.1%#14 | — |
| CNTN | $162M#12 | — | 0.4x#1 | — | — | -194.5%#11 | — | -7.9%#5 | — | — | -29.3%#8 | — |
| LFCR | $158M#13 | — | — | 1.2x#3 | 0.5%#5 | -422.5%#12 | -13.4%#3 | — | -28.7%#3 | 3#1 | -47.4%#10 | — |
| SPRB | $156M#14 | — | 1.9x#9 | — | -100.0%#6 | 26.5%#5 | — | -46.5%#8 | — | — | 536.0%#1 | — |
| NRXP | $145M#15 | — | — | 118.6x#7 | — | -13.9%#9 | -1324.4%#6 | — | — | — | 13.7%#7 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice